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IMPORTANCE Moving tomultigene testing for all womenwith breast cancer (BC) could
identify manymoremutation carriers who can benefit from precision prevention. However,
the cost-effectiveness of this approach remains unaddressed.
OBJECTIVE To estimate incremental lifetime effects, costs, and cost-effectiveness of
multigene testing of all patients with BC compared with the current practice of genetic
testing (BRCA) based on family history (FH) or clinical criteria.
DESIGN, SETTING, AND PARTICIPANTS This cost-effectivenessmicrosimulationmodeling study
compared lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of
all unselected patients with BC (strategy A) with BRCA1/BRCA2 testing based on FH or clinical
criteria (strategy B) in United Kingdom (UK) and US populations. Data were obtained from
11 836 patients in population-based BC cohorts (regardless of FH) recruited to 4 large
research studies. Data were collected and analyzed from January 1, 2018, through June 8,
2019. The time horizon is lifetime. Payer and societal perspectives are presented.
Probabilistic and 1-way sensitivity analyses evaluate model uncertainty.
INTERVENTIONS In strategy A, all womenwith BC underwent BRCA1/BRCA2/PALB2 testing.
In strategy B, only womenwith BC fulfilling FH or clinical criteria underwent BRCA testing.
Affected BRCA/PALB2 carriers could undertake contralateral preventive mastectomy; BRCA
carriers could choose risk-reducing salpingo-oophorectomy (RRSO). Relatives of mutation
carriers underwent cascade testing. Unaffected relative carriers could undergomagnetic
resonance imaging or mammography screening, chemoprevention, or risk-reducing
mastectomy for BC risk and RRSO for ovarian cancer (OC) risk.
MAIN OUTCOMES ANDMEASURES Incremental cost-effectiveness ratio (ICER) was calculated
as incremental cost per quality-adjusted life-year (QALY) gained and compared with standard
£30000/QALY and $100000/QALY UK and US thresholds, respectively. Incidence of OC,
BC, excess deaths due to heart disease, and the overall population effects were estimated.
RESULTS BRCA1/BRCA2/PALB2multigene testing for all patients detected with BC annually
would cost £10 464/QALY (payer perspective) or £7216/QALY (societal perspective) in the
United Kingdom or $65 661/QALY (payer perspective) or $61 618/QALY (societal perspective)
in the United States compared with current BRCA testing based on clinical criteria or FH. This
is well below UK and US cost-effectiveness thresholds. In probabilistic sensitivity analysis,
unselectedmultigene testing remained cost-effective for 98% to 99% of UK and 64% to
68% of US health system simulations. One year’s unselectedmultigene testing could prevent
2101 cases of BC and OC and 633 deaths in the United Kingdom and 9733 cases of BC and OC
and 2406 deaths in the United States. Correspondingly, 8 excess deaths due to heart disease
occurred in the United Kingdom and 35 in the United States annually.
CONCLUSIONS AND RELEVANCE This study found unselected, high-risk multigene testing for
all patients with BC to be extremely cost-effective compared with testing based on FH or
clinical criteria for UK and US health systems. These findings support changing current policy
to expand genetic testing to all womenwith BC.
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C urrent national and international guidelines recom-mendgenetic testing inwomenwithbreast cancer (BC)whofulfill recognizedorestablished familyhistory (FH)
orclinicalcriteria.Thesecriteriaaresurrogates forBRCA (BRCA1
[OMIM 113705] andBRCA2 [OMIM600185]) probability, with
genetic testing usually offered at approximately a 10% prob-
ability threshold of being a BRCA carrier.1,2 Being a BRCA
(mutation) carrier refers to carrying an inheritable genetic
pathogenic variant that predisposes todevelopment ofBRCA-
associated cancers. However, patients with BC and genetic
pathogenicvariantsdonotalwayshaveapositiveFH,andthese
criteriamiss a largeproportion (approximately 50%)ofpatho-
genic variant carriers.3-5 A genetic testing strategy based on
clinical criteria or FH depends on the patient and their physi-
cian’s awareness and understanding of the importance of
FH, FH accuracy, communication within or between fami-
lies, and timely referrals to clinical geneticsdepartments. Lim-
ited awareness by health care professionals and the public,
complexity of the current structure, restricted genetic coun-
seling services, andcurrent testingpathwayshave fostered re-
stricted access and massive underuse of genetic testing
services.6-8 Only 20% to 30% of eligible patients are referred
and access testing, and97%of estimated carriers in thepopu-
lation remain unidentified,7 missing substantial opportuni-
ties for precision prevention.6 Testing all patients with BC at
diagnosis can increase testing access and uptake and identify
manymore pathogenic variant carriers for screening andpre-
vention. We herein evaluate the cost-effectiveness of this al-
ternative approach of providing genetic testing to all patients
with BC regardless of FH.
Knowing a patient’s genetic pathogenic variant status is
important for themanagement andprognosis ofBC.Afteruni-
lateral BC, pathogenic variant carriers can choose contralat-
eral prophylacticmastectomy (CPM) to reduce their risk of de-
veloping contralateral BC and opt for surgical prevention of
ovarian cancer (OC). Cancer-affected carriersmaybecomeeli-
gible for novel drugs (eg, poly [adenosine diphosphate ri-
bose]polymerase [PARP] inhibitors) andotherprecisionmedi-
cine–based therapeutics through clinical trials.9 A major
advantage of genetic testing is enabling testing among rela-
tives of BC pathogenic variant carriers in order to identify un-
affected relatives carrying pathogenic variants for early diag-
nosis andcancerprevention.BRCA1/BRCA2carriershavea 17%
to 44% risk of developing OC and 69% to 72% risk of BC to 80
years of age.10PALB2 (OMIM610355) is a recently established
high-penetrance BC gene associated with a 44% BC risk.11 A
number of risk management options are available for unaf-
fected relatives with pathogenic variants. To reduce OC risk,
BRCA1/BRCA2 pathogenic variant carriers can undergo
risk-reducing salpingo-oophorectomy (RRSO).12,13 To reduce
BC risk, BRCA1/BRCA2/PALB2 pathogenic variant carriers
can be offered enhanced magnetic resonance imaging and
mammography screening,14,15 risk-reducing mastectomy
(RRM),16 or chemoprevention with selective estrogen recep-
tor modulators.17
Current restricting of testing to FH- or clinical criteria–
based selectionmisses important opportunities topreventBC
and OC in unaffected individuals. In this study, we obtained
data from 4 large BC clinical trials and/or research cohorts in
the United States, United Kingdom, and Australia. We used
modeling toestimatedownstreamhealtheffects andcosts and
explore the cost-effectiveness of multigene BRCA1/BRCA2/
PALB2 testing for all cases with BC compared with current
BRCA testing based on clinical criteria or FH alone. We re-
strict this analysis to BRCA1/BRCA2/PALB2, keeping in mind
the principles of theACCE framework (analytic validity, clini-
cal validity, clinical utility and associated ethical/legal/social
implications)18 advocated for clinical applicability of genetic
testing.18,19
Methods
This analysis received full ethics approval from the Institute
of Child Health/Great Ormond Street Hospital Research
Ethics Committee as well as the London School of Hygiene
and Tropical Medicine Ethics Committee, waiving informed
consent for the use of anonymized data. A patient and
public involvement statement is found in eMethods 4 in the
Supplement.
Data were collected and analyzed from January 1, 2018,
through June 8, 2019. We obtained data on FH by age from
11 836 women diagnosed with invasive BC, including (1) 1389
unselectedpatientswithBColder than45yearswhowere iden-
tified among 57902 women in the Predicting Risk of Breast
Cancer Screening study, a large-scale studywithin theGreater
Manchester UK National Health Service Breast Screening
Programme20; (2) 2885patientswithBCyounger than40years
from 127 UK hospitals in the Prospective Outcomes in Spo-
radic vs Hereditary Breast Cancer study21; (3) 5892 unse-
lected patients with BC older than 40 years among 132 139
womenenrolled in theKaiser PermanenteWashingtonBreast
CancerSurveillanceConsortiumregistrywhounderwentmam-
mography screening from 1996 to 201422; and (4) 1670 pa-
tientswithBCyounger andolder than40yearswhowere ran-
domlyselected fromtheunselectedpopulation–basedBCcases
Key Points
Question Is unselected genetic testing of all womenwith breast
cancer cost-effective compared with testing based on clinical
criteria or family history?
Findings In this cost-effectiveness microsimulationmodeling
study incorporating data from 11 836women, unselected
BRCA1/BRCA2/PALB2 testing at breast cancer diagnosis was
extremely cost-effective compared with BRCA1/BRCA2 testing
based on clinical criteria or family history for UK and US health
systems, with incremental cost-effectiveness ratios of £10 464
or £7216 and $65 661 or $61 618 per quality-adjusted life-year,
respectively. One year’s unselected panel genetic testing could
prevent 2101 cases of breast or ovarian cancer and 633 deaths in
the United Kingdom and 9733 cases and 2406 deaths in the
United States.
Meaning These findings support changing current policy to
expand genetic testing to all womenwith breast cancer.
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from the Australian Breast Cancer Family Study.23 The pro-
portionof cases fulfillingFHorclinical criteria for testingbased
on at least a 10% BRCA1/BRCA2 probability thresholdwas es-
timated using standard risk models (eg, BOADICEA [UK and
Australian data] and BRCAPRO [US data]).24,25 We thus ob-
tained the proportion fulfilling FH or clinical criteria (herein-
after referred to as FHpositive) forBRCA testing by age group
among unselected BC cases in each setting (eTable 1 in the
Supplement). The women in these cohorts are predomi-
nantlywhite and representative of aWestern population eth-
nicity (details in eTable 1 in the Supplement). We obtained
population-based BC incidence data by age from Cancer Re-
search UK 201526 for the UK analysis and fromUS Cancer Sta-
tistics 201527 for the US analysis. Thenwe estimated the total
number of FH-positive BC cases based on the number of new
invasive BC cases by age group in the UK andUS populations.
Model and Genetic Testing Strategy
We developed an individual-level microsimulation model
(illustrated and described in Figure 1 and Figure 2) (TreeAge
Pro 2018; TreeAge Software) to analyze costs and effects of
BRCA1/BRCA2/PALB2 testing for all patients with BC (strat-
egy A) compared with the current practice of BRCA testing
using clinical- or FH-based criteria (≥10% pathogenic variant
risk) (strategyB).Microsimulationpermits individual hetero-
geneity in gene types and ages and can track individual pa-
tient history if the memory of events (eg, risk-reducing op-
tions) affects future cycles. Themodel assumes all patients in
the unselected testing arm (strategy A) and only those fulfill-
ing clinical orFHcriteria in strategyBareofferedgenetic coun-
seling and testing.Weassumeall eligible patients undergo ge-
netic testing inourbase-case analysis. If patientshadaBRCA1/
BRCA2/PALB2 pathogenic variant, their first-degree relatives
undergo testing for the familial pathogenic variant. If the
first-degree relative had a BRCA1/BRCA2/PALB2 pathogenic
variant, second-degree relativesundergo testing.We incorpo-
rate a 6.4% variant of uncertain significance (VUS) rate
(BRCA1, 1.23%;BRCA2, 3.29%; andPALB2, 1.86%)28 and8.7%
pathogenic or likelypathogenic reclassification rate forVUS.29
Figure 1 provides a schema of the model with respect to
patientswithBC. In theunselectedtestingarm,allpatientswith
BC are offered genetic testing and are classified as pathogenic
Figure 1. Model Structure
Testing option
Unselected testing
Patients
VUS
Pathogenic
variant carriers Noncarriers
Reclassification
Yes No
Relatives Patients Relatives
Positive FH Negative FH
Testing based on
clinical criteria or FH
Dead
Germline
ipsilateral BC
BC and OC
Germline
contralateral BC
PALB2
undetected
BRCA
undetected
BRCA1/PALB2
negativea
PALB2
positive
BRCA1/2
positive
CPM
RRSO
No CPM
RRSO
CPM
No RRSO
Sporadic BC
No CPM
No RRSO
Schematic diagram shows the
microsimulationmodel structure for
unselected and clinical criteria–or
family history (FH)–based panel
genetic testing for patients with
breast cancer (BC). CPM indicates
contralateral prophylactic
mastectomy; OC, ovarian cancer;
RRSO, risk-reducing
salpingo-oophorectomy; and
VUS, variant of uncertain significance.
a Includes individuals testing negative
for BRCA1/BRCA2/PALB2mutations
and VUS not reclassified as
pathologic variants.
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variant carriers, VUS carriers, or noncarriers. A proportion
(8.7%) of patients with VUS results will subsequently get re-
classified as pathogenic variant carriers. Identified BRCA1/
BRCA2pathogenic variant carriers are offered options of CPM
and RRSO, and identified PALB2 pathogenic variant carriers
are offeredCPM.Dependingon theprobability of patients un-
dertaking a CPM and/or RRSO, theymay progress to germline
contralateral BCor bothBCandOC.They alsohave aprobabil-
ity of dying due to germline BC. Patients who do not progress
ordiewould stay in the stateof germline ipsilateral BCandun-
dertake the next cycle. Patients with negative findings for
BRCA1/BRCA2/PALB2have sporadicBC.Age-dependentprob-
abilities allowthemtodevelop sporadicOCandprogress to the
health state of BC and OC. They also have a probability of dy-
ingdue to sporadicBC.Womenwhodonot progress toBCand
OC or die would stay in the health state of sporadic BC to un-
dertake the next cycle.
In the clinical criteria/FH testing arm, patients with posi-
tiveFH (fulfilling clinical criteria) undergo genetic testing and
are classified as pathogenic variant carriers, VUS carriers, or
noncarriers.AproportionofpatientswithVUSresultswill sub-
sequently be reclassified as pathogenic variant carriers. Pa-
tientswithnegativeFHdonotundertakegenetic testing.They
can be undetected BRCA1/BRCA2 pathogenic variant carri-
ers, undetected PALB2 pathogenic variant carriers, or nega-
tive forBRCA1/BRCA2/PALB2.OptionsofCPMand/orRRSOand
diseaseprogression for identifiedBRCA1/BRCA2/PALB2patho-
genic variant carriers anddiseaseprogression forpatientswho
are BCnegative forBRCA1/BRCA2/PALB2 is the same as those
in the unselected testing arm described above. Undetected
BRCA1/BRCA2pathogenic variant carriers arenotofferedCPM
orRRSO,andundetectedPALB2pathogenicvariant carriersare
not offered CPM. Depending on the baseline risk (no risk-
reducing options), they progress to germline contralateral BC
or both BC and OC. They also have a probability of dying due
to germline BC. Patients who do not progress or die would
stay in the state of germline ipsilateral BC and undertake the
next cycle.
Figure 2 provides a schema of the model with respect to
unaffected relatives identified through cascade testing. Pro-
gression through themodel depends on theprobabilities pro-
vided in eTable 2 in the Supplement. In the unselected test-
ing arm, relatives of pathogenic variant carriers with BC are
offeredBRCA1/BRCA2/PALB2 genetic testing and classified as
pathogenic variant carriers or noncarriers. Relatives of pa-
tients with BC and VUS (8.7%) who are reclassified as patho-
genicvariantcarriersarealsoofferedpredictiveBRCA1/BRCA2/
PALB2 testing. Relatives identified with BRCA1/BRCA2
Figure 2. Model Structure
Testing option
Unselected testing
Patients
VUSPathogenicvariant carriers Noncarriers
Dead
Germline OCGermline BC
BC and OC
No cancerc Sporadic OC
Only BRCA1/2
testing offered
Reclassification
Relatives Patients Relatives
Positive FH Negative FH
Testing based on
clinical criteria or FH
PALB2
undetected
BRCA
undetected
BRCA/PALB2
negativea
PALB2
positiveb
BRCA1/2
positive
RRM
RRSO
No RRM
RRSO
RRM
No RRSO
Sporadic BC
No RRM
No RRSO
yes no
BRCA/PALB2 BRCA
Schematic diagram shows the
microsimulationmodel structure for
unselected and clinical criteria–or
family history (FH)–based panel
genetic testing for relatives of
patients with breast cancer (BC).
CPM indicates contralateral
prophylactic mastectomy;
OC, ovarian cancer;
RRM, risk-reducingmastectomy;
RRSO, risk-reducing
salpingo-oophorectomy; and
VUS, variant of uncertain significance.
a Includes individuals testing negative
for BRCA1/BRCA2/PALB2mutations
and VUS not reclassified as
pathologic variants.
b In themodel structure for relatives,
PALB2-positive individuals are
identified only through the
unselected testing arm. Relatives in
the clinical criteria/FH testing arm
only undergo BRCA1/BRCA2 testing.
c Unaffected relatives can progress
from no cancer to germline BC
(BRCA1/BRCA2/PALB2), germline OC
(BRCA1/BRCA2), sporadic BC, or
sporadic OC (or remain in that
health state).
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pathogenicvariants areofferedoptionsofRRMandRRSO, and
those identified with PALB2 pathogenic variants are offered
RRM. Unaffected relatives can also opt for chemoprevention
forBC.Dependingon theprobabilityofpathogenicvariant car-
riers undertaking an RRM and/or RRSO (with or without che-
moprevention), theyprogress to germlineBC (BRCA1/BRCA2/
PALB2) or germline OC (BRCA1/BRCA2) or stay in the health
state of no cancer. They have a probability of background all-
causemortality.Womenwho are negative for BRCA1/BRCA2/
PALB2 progress to sporadic BC or sporadic OC or stay in the
health state of no cancer. They have a probability of back-
ground all-cause mortality.
In the clinical criteria/FH testing arm, relatives of identi-
fied patients with BRCA1/BRCA2 mutation undergo predic-
tive BRCA1/BRCA2 genetic testing. They are classified as
pathogenic variant carriers or noncarriers. Relatives of
patients with BC and VUS who are reclassified as pathogenic
variant carriers also undergo predictive BRCA1/BRCA2 test-
ing. PALB2 pathogenic variant carriers cannot be detected
when only FH-based BRCA1/BRCA2 genetic testing is
offered. Relatives of patients with negative FH may be unde-
tected BRCA1/BRCA2 pathogenic variant carriers, unde-
tected PALB2 pathogenic variant carriers, or negative for
BRCA1/BRCA2/PALB2. The options of RRM and RRSO for
identified carriers are the same as in the unselected testing
arm. For identified BRCA1/BRCA2/PALB2 pathogenic variant
carriers and noncarriers (BRCA1/BRCA2/PALB2 negative),
the disease progression is the same as in relatives in the
unselected testing arm. Undetected BRCA1/BRCA2 patho-
genic variant carriers are not offered RRM or RRSO, and
undetected PALB2 pathogenic variant carriers are not
offered RRM. Depending on the baseline risk, they progress
to germline BC or germline OC or stay in a no cancer health
state. They also have a probability of background all-cause
mortality.
As shown in themodel, unaffectedBRCA1/BRCA2/PALB2
pathogenic variant carriers can choose RRM and/or chemo-
prevention to reduce BC risk and RRSO (BRCA1/BRCA2 only)
to reduce OC risk in addition to undertaking enhanced BC
screening. Patients with BC found to have pathogenic vari-
ants can opt for CPM. Although initial studies suggested that
premenopausalRRSO is associatedwith reducedBCrisk,13,30,31
more recent data contradict this observation, especially in
BRCA1,32 raising uncertainty around this issue. We explored
no reduction in BC risk in our scenario analysis. We incorpo-
rated the excess risk andmortality due to coronary heart dis-
ease (CHD) after premenopausal oophorectomy (after RRSO)
for premenopausalwomenwhodonot takehormone replace-
ment therapy (HRT) (absolutemortality increase, 3.03%).33,34
In our model, a hypothetical cohort of patients with BC and
their cancer-free relatives can transition to different health
states, including no cancer, germline ipsilateral BC, germline
contralateral BC, sporadic BC, germline OC, sporadic OC, and
both BC and OC. Cancer incidence was estimated by sum-
ming theprobabilities ofpathwaysending inOCorBC.Thepo-
tential population effect was calculated by estimating addi-
tional reduction in BC and OC incidence obtained through
testing the entire population of BC cases occurring annually
in UK and US women. In line with the National Institute of
Health and Clinical Excellence (NICE) economic evaluation
guidelines, costs and outcomes are discounted at 3.5%.35
Probabilities
Model probabilities for the different pathways are shown in
eTable 2 in the Supplement. The age-specific incidences of BC
andOCamong the general population are obtained fromCan-
cerResearchUK201526,36 andUSCancer statistics 2015.27 The
age-specific incidence of BC and OC for BRCA1/BRCA210 car-
riers and of BC for PALB2 carriers,11 along with the incidence
of contralateral BCafter first BCdiagnosis,10 areobtained from
the literature.
Number and Age Distribution of Relatives
We used the number of new BC cases by age groups in the
United Kingdom and United States to calibrate the age distri-
butionofpatients in themodel.26,27 Themeannumberof first-
or second-degree relativesandtheir ages relative to indexcases
are derived from data from the Office for National Statistics
(in the United Kingdom)37 and the National Center for Health
Statistics (in the United States)38 (details in eTable 3 in the
Supplement). We used life tables based on age and sex to es-
timate the probability of being alive for relatives at different
ages and to calculate the number and age distribution of rela-
tives who need to undergo testing.
Costs
All costs are reported at 2016 prices. The analysis was con-
ducted from payer and societal perspectives. Costs included
genetic testing, pretest and posttest genetic counseling,39,40
BC, OC, excess CHD, and productivity loss. In line with NICE
recommendations, futurehealthcarecostsnotassociatedwith
BC,OC,orCHDwerenot considered.35Asummaryof costs and
detailed explanation are given in eTable 4 in the Supplement
(medical costs) andeMethods 1 in the Supplement (costs from
productivity loss).
Life-Years
Our analysis incorporates lifetime risks and long-term conse-
quences to provide a lifetime horizon. Female life tables
from the Office of National Statistics (UK women)41 and the
National Center for Health Statistics (US women)42 were
used to estimate life expectancy by 80 years for women who
did not develop OC or BC. We assumed the median age
for undergoing RRM and RRSO in unaffected pathogenic
variant carriers was 37 and 40 years, respectively.43 We also
explored older age at RRM (42 years) and RRSO (46 years)
reported in a scenario analysis.44 Survival after BC and OC
(from diagnosis to death) was modeled using 10-year sur-
vival data. Details of survival estimates used are given in
eMethods 2 in the Supplement.
Quality-Adjusted Life-Years
Aquality-adjusted life-year (QALY) is ameasurementofhealth
outcomes ineconomicevaluations recommendedbyNICE.An
explanation of QALY and utility scores in the model is given
in eMethods 3 in the Supplement.
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Statistical Analysis
In the microsimulation model, we used the number of
annual new BC cases (United Kingdom, 54 483; United
States, 242463) and corresponding female relatives (United
Kingdom, 215401; United States, 993 757) by age for running
simulations. Internal validation of the model was under-
taken through a process of descriptive, technical, and face
validity.45Wecalculated the incremental cost-effectiveness ra-
tio (ICER)bydividing thedifference in lifetimecostsby thedif-
ference in lifetime effects (QALYs) between the 2 strategies
as follows: (Cost of Strategy A − Cost of Strategy B)/(Effect of
StrategyA−Effect of StrategyB). By comparing the ICERwith
thewillingness-to-pay (WTP) thresholdof £30000/QALY (UK
analysis)46 and $100000/QALY (US analysis),47,48 we deter-
minedwhether genetically testing all patientswithBC is cost-
effective comparedwith testingbasedonclinical criteriaorFH
alone. We undertook a number of scenario analyses, includ-
ing (1) no reduction in BC risk due to RRSO; (2) nil HRT adher-
ence; (3) lower genetic testing uptake rate (70%) in patients
with BC and relatives; (4) 15% BRCA1/2 pathogenic variant
prevalence inpatientswithBC fulfilling clinical criteria or FH;
(5) double cost of genetic counseling (United Kingdom, £40;
United States, $80); (6) highermedian age for RRM (42 years)
and RRSO (46 years) in unaffected pathogenic variant carri-
ers; and (7) the maximum values of cost(s) of genetic testing
atwhich the ICERs reach theWTP thresholds tomaintain cost-
effectiveness of unselected multigene testing (strategy A).
We performed extensive 1-way and probabilistic sensitiv-
ity analyses to explore model parameter uncertainty. In the
1-way sensitivity analysis, eachvariable or parameterwasvar-
ied individually toassess theeffectonresults.Probabilitiesand
utility scoreswerevariedby their95%CIsor rangewhereavail-
able or by±10%, and costswere varied by±30%. In theproba-
bilistic sensitivity analysis, all of the input variableswere var-
iedsimultaneously (as recommendedbyNICE).49Assuggested
in the literature,50 costswere given a γdistribution; quality of
life, a log-normal distribution; and probability, a β distribu-
tion. For probabilistic sensitivity analysis, we obtained 1000
estimates of incremental costs and effects by sampling from
thedistributionsof eachvariable.A cost-effectiveness accept-
ability curve was then plotted to show the probability of ge-
netically testing all patients, with BC (strategy A) being cost-
effective at different WTP thresholds.
Results
Compared with the current practice of genetic testing based
on clinical criteria or FH, offering unselected multigene test-
ing for all patients diagnosed annually with BC (54483 in the
UnitedKingdomand 242463 in theUnited States) and subse-
quent predictive/cascade testing of relatives (strategy A) was
highly cost-effective. The ICER for the UK payer perspective
was £10464/QALY (credible interval, £8347/QALY to £28965/
QALY) and for the societal perspective, £7216/QALY (credible
interval, £6194/QALY to £23 575/QALY). The ICER for the US
payer perspective was $65 661 per QALY (credible interval,
$46613/QALY to $248 185/QALY) and for the societal perspec-
tive, $61618/QALY(credible interval, $42927/QALYto$221781/
QALY). The lifetime costs, QALYs, and population effects (re-
duced cancer incidence anddeaths) forUKandUSwomenare
shown in Table 1 and Table 2. Strategy A was associated with
an additional 419-day increase in life expectancy for UK and
298days forUSBRCA1/BRCA2/PALB2pathogenic variant car-
riers. Oneyear’s unselected genetic testing of all patientswith
BCcouldprevent anadditional 1142BCcases and959OCcases
in the United Kingdom and 5478 BC cases and 4255 OC cases
in theUnitedStates (Table2).This findingcorresponds toavert-
ing 633 deaths due to cancer in UK populations and 2406
deaths due to cancer in US populations during a lifetime ho-
rizon (Table 2). The corresponding excess deaths due to heart
disease were 8 in UK and 35 in US women annually.
The 1-way sensitivity analysis (eFigure 1A-D in the
Supplement) indicates that pathogenic variant prevalence,
costs, utility scores, and transition probabilities had little
individual influence on the cost-effectiveness of unselected
genetic testing (strategy A) from a payer or a societal perspec-
tive. Scatterplots for the UK and US analyses are given in
eFigure 2 in the Supplement and show that all simulations
and iterations lie in the northeast quadrant, indicating unse-
lected testing was always more effective. The ICERs are lower
than the UK and US WTP thresholds at the upper and lower
limits of these variables. Probabilistic sensitivity analysis
(Figure 3) shows that at the £30000/QALY or $100000/QALY
thresholds, 98% (UK payer perspective), 99% (UK societal
perspective), 64% (US payer perspective), or 68% (US societal
perspective) of simulations indicate that unselected genetic
testing is cost-effective compared with testing based on FH
or clinical criteria.
The number of pathogenic variant carriers among unaf-
fected female relatives identified through cascade testingwas
1.41 in the United Kingdom and 1.46 in the United States per
index pathogenic variant carrier with BC (details in eTable 4
in theSupplement). Scenario analyses arepresented inTable 1.
Unselected testingwas cost-effective frompayer and societal
perspectives, evenwith alternative scenarios of no reduction
in BC risk due to RRSO (ICER payer perspective, £10 532/
QALY or $66 136/QALY; ICER societal perspective, £7291/
QALY or $62 102/QALY); nil HRT adherence (ICER payer per-
spective, £11 303/QALY or $89 705/QALY; ICER societal
perspective, £7870/QALY or $85 337/QALY); and lower (70%)
genetic testing uptake rate in patients with BC and relatives
(ICERpayerperspective, £10991/QALYor $71006/QALY; ICER
societal perspective, £8046/QALY or $67 285/QALY). Al-
though theprobabilityofbeingaBRCA1/BRCA2carrier in those
fulfilling FHor clinical genetic testing criteriawas reported at
approximately 10%,51,52 we also explored a scenario of over-
all 15%BRCA1/BRCA2carrierprobability.Thisvariablehadonly
aminimal effect on ICERs from the payer (£10 585/QALY) and
societal (£7332/QALY)perspectivesamongUKwomenandfrom
the payer ($66694/QALY) and societal ($62646/QALY) per-
spectives among US women. The upper limit of genetic test-
ing costs at which unselected genetic testing for all patients
withBCwouldstill remaincost-effectiveat theestablishedWTP
thresholdswas approximately £1626 from the payer perspec-
tive and £1868 from the societal perspective for theUKhealth
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Table 2. Population Effect of Genetic Testing for PatientsWith BC
Estimated Effect
Testing in All Patients With BC Testing Based on FH Differences
Patients Relatives Patients Relatives Patients Relatives Total
UK germline cancer
No. of BC cases 364a 1965 684a 2787 320a 822 1142
No. of OC cases 447 1882 871 2417 424 535 959
No. of BC and OC deaths 451 988 748 1325 296 337 633
US germline cancer
No. of BC cases 1639a 8727 3230a 12 614 1591a 3887 5478
No. of OC cases 2087 8655 3916 11 081 1829 2426 4255
No. of BC and OC deaths 1555 4168 2621 5508 1066 1340 2406
Abbreviations: BC, breast cancer; FH, family history; OC, ovarian cancer.
a Indicates contralateral BC cases in patients with unilateral BC.
Table 1. Lifetime Discounted Costs and Effects perWoman and ICER After Genetic Testing for All PatientsWith BCa
Country
Testing All Patients With BC Testing Based on Family History ICER
Health Effects Costsb Health Effects Costsb Cost/LYGb Cost/QALYb
LYGs QALYs Payer Societal LYGs QALYs Payer Societal Payer Societal Payer Societal
Baseline
United
Kingdom
18.772 17.941 7213 11 147 18.755 17.922 7016 11 011 11 817 8149 10 464 7216
United
States
18.652 17.813 32 721 36 561 18.639 17.798 31 724 35 625 82 789 77 691 65 661 61 618
No Reduction in BC Risk Due to RRSOc
United
Kingdom
18.772 17.941 7214 11 148 18.755 17.922 7016 11 011 11 846 8201 10 532 7291
United
States
18.652 17.813 32 724 36 564 18.639 17.798 31 724 35 625 82 902 77 844 66 136 62 102
No HRT Adherenced
United
Kingdom
18.771 17.940 7218 11 152 18.755 17.922 7016 11 011 12 706 8846 11 303 7870
United
States
18.651 17.812 33 013 36 852 18.639 17.798 31 751 35 652 113 342 107 823 89 705 85 337
Lower Uptake Rate of Genetic Testing in Patients and Relativese
United
Kingdom
18.766 17.934 7132 11 096 18.755 17.922 7009 11 007 11 363 8319 10 991 8046
United
States
18.644 17.804 32 299 36 170 18.637 17.796 31 691 35 595 80 043 75 849 71 006 67 285
15% Probability of Being a BRCA Carrier in Patients With Positive FHf
United
Kingdom
18.771 17.941 7213 11 147 18.755 17.923 7022 11 015 11 973 8293 10 585 7332
United
States
18.653 17.814 32 723 36 563 18.641 17.800 31 759 35 657 84 453 79 326 66 694 62 646
Double Cost of Counselingg
United
Kingdom
18.772 17.941 7220 11 154 18.755 17.922 7016 11 011 12 189 8521 10 794 7546
United
States
18.652 17.813 32 734 36 574 18.639 17.798 31 725 35 625 83 798 78 701 66 462 62 419
Older Ages for RRM and RRSO in Unaffected Pathogenic Variant Carriersh
United
Kingdom
18.770 17.938 7216 11 165 18.755 17.922 7016 11 013 13 181 10 043 12 214 9306
United
States
18.650 17.811 32 722 36 578 18.639 17.798 31 720 35 622 92 304 88 063 77 715 74 144
Abbreviations: BC, breast cancer; FH, family history; HRT, hormone
replacement therapy; ICER, incremental cost-effectiveness ratio; LYG, life-years
gained; QALY, quality-adjusted life-year; RRM, risk-reducingmastectomy;
RRSO, risk-reducing salpingo-oophorectomy.
a Costs and outcomes are discounted at 3.5%. Data are given at baseline (for the
base case) and for separate scenarios.
b Costs are given in dollars for the United States and pounds sterling for the
United Kingdom.
c Probability P 15 = 1 (eTable 2 in the Supplement).
d Probability P 21 = 0 (eTable 2 in the Supplement).
e Indicates a genetic testing uptake rate of 70%.
f Probability P 4 = 0.15 (eTable 2 in the Supplement).
g Indicates £40 in the United Kingdom and $80 in the United States.
h Indicates ages 42 and 46 years for RRM and RRSO, respectively.
Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology Published online October 3, 2019 E7
Downloaded From: https://jamanetwork.com/ by a Queen Mary, University of London User  on 10/03/2019
systemand$2432 from thepayer perspective and $2679 from
the societal perspective for the US health system.
Lower RRSO and RRM rates are reported in some
populations.53 The minimum RRSO uptake rate to maintain
cost-effectiveness was 29% from the payer perspective or
28% from the societal perspective for the United States
(ICER, $100000/QALY), butunselectedBCgenetic testingwas
cost-effective in theUnitedKingdomeven if theRRSOratewas
nil (ICERfromthepayerperspective, £26392/QALY; ICERfrom
thesocietalperspective, £23802/QALY).Thestrategywascost-
effective even if RRM rates in unaffected relatives approached
0 (UK ICER from the payer perspective, £9969/QALY;UK ICER
from the societal perspective, £7041/QALY; US ICER from the
payerperspective, $67235/QALY;USICERfromthesocietalper-
spective, $63643/QALY). However, if RRMuptakewas 0, then
the minimum RRSO uptake rate to maintain cost-effective-
ness at the WTP thresholds (United States, $100000/QALY;
UnitedKingdom, £30000/QALY)was 33% (payerperspective)
or 32% (societal perspective) in the US health system and
5% (payer perspective) or 4% (societal perspective) in the UK
health system.
Discussion
Our analysis addresses a topical and important issue of unse-
lectedmultigene testing for all patients with BC.We show for
the first time, toourknowledge, thatmultigenetesting forhigh-
penetrance BC pathogenic variants of well-established clini-
cal utility is more cost-effective and outperforms standard
Figure 3. Cost-effectiveness Acceptability Curves (Probabilistic Sensitivity Analyses)
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Probabilistic sensitivity analysis in which all model parameters/variables are
varied simultaneously across their distributions to further explore model
uncertainty. The results of 1000 simulations were plotted on a
cost-effectiveness acceptability curve showing the proportion of simulations
that indicated that the intervention was cost-effective at different
willingness-to-pay (WTP) thresholds. A and B, The dotted line marks the
proportion of simulations found to be cost-effective at theWTP threshold of
£30000 per quality-adjusted life-year (QALY) in the UK analysis. At the
£30000/QALYWTP threshold from the payer perspective, 2% simulations are
cost-effective for testing based on clinical criteria or family history (FH) and
98% simulations are cost-effective for unselected genetic testing; from the
societal perspective, 1% simulations are cost-effective for testing based on
clinical criteria or FH and 99% simulations are cost-effective for unselected
genetic testing. C and D, The dotted line marks the proportion of simulations
found to be cost-effective at theWTP threshold of $100000/QALY in the US
analysis. At the $100000/QALYWTP threshold from the payer perspective,
36% simulations are cost-effective for testing based on clinical criteria or FH
and 64% simulations are cost-effective for unselected genetic testing; from the
societal perspective, 32% simulations are cost-effective for testing based on
clinical criteria or FH and 68% simulations are cost-effective for unselected
genetic testing.
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BRCA testingdrivenbyclinical criteria orFHalone.Moving to-
ward such a program could lead to 1142 fewer BC cases, 959
fewer OC cases, and 663 fewer deaths due to BC or OC in UK
women and 5478 fewer BC cases, 4255 fewer OC cases, and
2406 fewerdeathsdue toBCorOC inUSwomenannually.Our
study provides QALY-based health outcomes that justify the
cost differences between the 2 strategies that are needed for
healthcareprofessionals,providers,andpolicymakers toguide
or direct resource allocation. The ICERs (£10464/QALY and
£7216/QALY in the United Kingdom and $65 661/QALY and
$61 618/QALY in the United States) lie well below the estab-
lished cost-effectiveness thresholds for the UK (£20000/
QALY to £30000/QALY) and the US ($100000/QALY) health
systems. Continuing with the current FH- or clinical criteria–
basedpolicyreflects importantopportunitiesmissedforBCand
OC prevention.
ComparisonWith Other Studies
Although earlier studies have reported cost-effectiveness of
BRCA testing at the 10% pretest probability threshold,54 we
report cost-effectiveness of unselected BRCA/PALB2 testing
irrespective of a priori mutation probability. Our findings are
in line with a recent, small Norwegian study (535 patients)
showing cost-effectiveness of BRCA testing for all patients
with BC.5 Our study is broader in scope and draws on amuch
larger sample size of population-based UK, US, and Austra-
lian patients with BC. Testing at cancer diagnosis has now
moved toward multigene testing. PALB2 is associated with
nonsyndromic, quasi-mendelian BC susceptibility (BC
risk, 44%), and magnetic resonance imaging screening
and RRM are now offered for pathogenic variants. Other
high-risk genes are identifiable as pleiotropic syndromic
(STK11, PTEN, or p53) or associated with only a small subset
(lobular), and all are very rare.19 In addition, reliable risk
estimates corrected for ascertainment bias are lacking.19
Although ATM and CHEK2 are included in some commercial
panels, clinical testing for these genes is not routine in most
centers. Risks conferred by these pathogenic variants are
lower (relative risk, approximately 1.5-2.0), and although
National Comprehensive Cancer Network guidelines support
breast screening, RRM is not routinely offered, FH needs
incorporation into risk assessment and management, and
many health care professionals believe that they fall below
the clinical intervention threshold.19 Hence, we incorporated
PALB2 along with BRCA but excluded other genes.
Implications
The current health care model of testing based on clinical
criteria or FH has numerous limitations. It misses a large
proportion of pathogenic variant carriers who fall below the
current clinical threshold.3,5 The current system is plagued
by massive underuse of genetic testing and missed opportu-
nities for BC and OC screening and prevention.6,7 Moving
toward unselected BC testing may give an impetus for pre-
vention in unaffected family members along with clinical
implications for the patient with BC. Pathogenic variant car-
riers with newly diagnosed BC can opt for bilateral mastec-
tomy rather than breast conservation at initial BC surgery.
Bilateral mastectomy reduces contralateral BC risk, may pro-
vide better options for breast reconstruction, and may obvi-
ate the need for adjuvant radiotherapy.55 The patients also
become eligible for therapeutic options, such as PARP inhibi-
tors. Addressing the increasing burden of long-term and
chronic disease, including cancer, is one of the world’s great-
est public health challenges and is important for future
viability of health systems across the world.56 The Milken
Institute estimates that improving prevention can cut mil-
lions of cases of chronic disease and reduce treatment costs
by billions.57 The applicability of genomics to medicine is
growing and expanding. Moving toward unselected multi-
gene testing for patients with BC can provide a huge stimu-
lus for precision prevention.
Existing genetic counseling services operating through
high-risk cancer genetics clinics do not have the resources or
manpower to deliver unselected genetic testing for all pa-
tients with BC given the large numbers of patients who re-
ceive a diagnosis annually. Hence, newer context-specific de-
liverymodelswill beneeded for implementing this approach.
These models may require pretest counseling to be under-
taken by nongenetic health care professionals who will need
to be trained for this. This approach of mainstreaming ge-
netic counseling and testing has recently been successfully
implemented inOC treatmentpathways.58,59Oncologists, sur-
geons, and clinical nurse specialists have provided pretest
counseling and genetic testing,58,59 with genetic services fo-
cusing on posttest counseling and support for women carry-
ingpathogenic variants.A similar approach couldwork for pa-
tients with BC. Examples of other delivery options include a
genetics service–coordinated nurse-led model,60 a genetics-
embeddedmodel (genetics health care professional or coun-
selor embedded in the cancer clinic),61,62 and telephone
counseling40,63,64 or telegenetics services65 for genetic coun-
seling and testing.
Going forward, most health care professionals who
practice medicine will need an increased understanding of
genetics and ability to counsel patients about this topic.8,66
As the volume of testing rises, the number of mutations and
VUS being diagnosed along with the need for correct inter-
pretation and management will increase. Implementation
will need to be accompanied by a process of training and
education for relevant physicians and other health care pro-
fessionals involved in the care pathway so that they can
understand the implications for management, including that
of VUS. This process is critical to ensure best evidence–based
care67 and to avoid unintended or inappropriate manage-
ment, such as downstream predictive testing, screening, or
prevention in VUS cases.68 Updated guidelines need to
reflect the importance of appropriate management. Appro-
priate clinical decision support tools can facilitate this trans-
formation. Another potential bottleneck to address is labora-
tory infrastructure to manage increased sample throughput.
Although some health systems have adequate capacity, oth-
ers may lack this infrastructure. Future research needs to
evaluate the effects and downstream outcomes of various
context-specific genetic testing implementation and man-
agement pathways for patients with BC.
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Strengths and Limitations
Our study has several strengths. The model incorporates un-
selected BC data from large population-based studies, up-to-
date information fromtheGeneticsCancerPredictionThrough
Population Screening study,69 published literature, and pub-
lic databases such as those of theOffice for National Statistics
(United Kingdom),37,41 National Center for Health Statistics
(United States),38,42 and Cancer Research UK.26,36We use the
current standard of clinical care (approach based on clinical
criteria or FH) as the comparator and present analyses from
thepayer and societal perspectives.Our analysis followsNICE
recommendations: QALYs to measure health outcomes;
cost-effectiveness analysis for health economic evaluation,49
integration of utility scores, discounting costs and outcomes
(rate, 3.5%), sufficiently longhorizon (lifetime) touncover im-
portant differences in costs and outcomes, and extensive and
thorough 1-wayandprobabilistic sensitivity analyses that sup-
port robustness and accuracy of results (eFigure 1 in the
Supplement and Figure 2). We include a detriment for CHD
mortality.33 Our costs include genetic testing, VUS manage-
ment, pretest and posttest genetic counseling, HRT use, and
protection from osteoporosis.
Our study has limitations related to modeling assump-
tions.Ourbaselinemodel assumes that allwomenwithBCand
their unaffected relatives undergo genetic testing. Although
very high (≤98%), genetic testing rates are reported in unse-
lected genetic testing at OC diagnosis, and corresponding ge-
netic testinguptakedata inunselectedpatientswithBCarenot
well established. Our scenario analysis reconfirms cost-
effectiveness at lower (70%) uptake rates. Although our base
model incorporates reduction in BC riskwith premenopausal
oophorectomy in keepingwithmany initial analyses,13,30,31,70
recent uncertainty surrounds this.32 Our scenario analysis re-
confirms cost-effectiveness even without this benefit. Al-
thoughgenetic testingcostshavefallendrastically, somehealth
care providers charge higher prices than our base-case as-
sumption. Nevertheless, unselected BC testing would re-
main cost-effective even at £1626 to £1868 in theUnitedKing-
dom or $2432 to $2679 in the United States, which is many
times greater than costs charged by most health care provid-
ers today. Another limitation is that our model incorporates
data predominantly from white women, which can limit in-
terpretation of generalizability to nonwhite populations.
Although we have incorporated disutility for RRSO and
RRM,surgicalpreventionmighthaveassociatedcomplications
(RRSO, approximately 3%-4%71;RRM,approximately 21%)72,73
thatneedtobefactored intothe informedconsentanddecision-
making process. Although premenopausal RRSO is not associ-
atedwithworseninggeneral qualityof life, poorer sexual func-
tionisreported(despiteHRT).74,75Thisoutcomeiscompensated
byextremelyhighsatisfaction ratesand reduction inperceived
cancer riskand/orworrywithRRSO.74,76Risk-reducingmastec-
tomyisnegativelyassociatedwithsexualpleasureandbodyim-
age.Thesedisadvantagesmaybeoffsetby reducedanxiety, im-
provedsocialactivity,77goodcosmeticsatisfactionrates,78,79and
lack of negative impact on sexual activity/habit/discomfort,77
anxiety/depression,orgenericqualityof life.77,80,81Weconfirmed
that unselectedmultigene testing remains cost-effective at re-
cently reportedolderagesofRRMandRRSO.44Thesurgicalpre-
vention(RRMandRRSO)ratesusedarebasedonestablishedUK
andUSdata.43,82However, theseratescanvary,with lowerrates
reported in somepopulations.53Thoseascertained frompopu-
lationtestingmayhavelowerBCrisksandresult in loweruptake,
particularly in theabsenceofdeathdue toBCandheavycancer
burdeninthefamily.Ourscenarioanalysesshowthatunselected
testing remains cost-effective at lower RRSO andRRM rates.
Conclusions
This study’s findings suggest that unselectedmultigene test-
ing for BC susceptibility genesBRCA1/BRCA2/PALB2 can sub-
stantially reduce future BC and OC cases and related deaths
comparedwith the current clinical strategy. Our analysis sug-
gests that an unselected testing strategy is extremely cost-
effective for UK and US health systems and provides a basis
for change in current guidelines and policy to implement
this strategy.
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